Cohance Lifesciences receives warning letter for its Nacharam formulation facility
From the USFDA
Pursuant to the USFDA inspection, Cohance Lifesciences has received a warning letter for the company's Nacharam formulation facility.The Company had earlier informed the Stock Exchanges that the facility was classified as Official Action Indicated (OAI), and the said Warning Letter is in continuation of the same.
The inspection was conducted by the USFDA from 04 August 2025 to 12 August 2025.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Feb 04 2026 | 12:32 PM IST